Doxorubicin exhibits strong and selective association with VEGF Pu22 G-quadruplex

Bilgen E., Persil Çetinkol Ö.

Biochimica et Biophysica Acta - General Subjects, vol.1864, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 1864
  • Publication Date: 2020
  • Doi Number: 10.1016/j.bbagen.2020.129720
  • Journal Name: Biochimica et Biophysica Acta - General Subjects
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Keywords: Doxorubicin, Anthracycline, G-quadruplex, DNA, Cancer, VEGF, INDUCED APOPTOSIS, HUMAN TELOMERASE, PROMOTER REGION, SMALL MOLECULES, DNA, DISCOVERY, SEQUENCE, CARDIOTOXICITY, ADRIAMYCIN, INSIGHTS
  • Middle East Technical University Affiliated: Yes

Abstract

Background: Vascular endothelial growth factor (VEGF), is upregulated in tumor cells and thus became a potential therapeutic target for anti-cancer drugs. Recent reports suggested the use of Doxorubicin (Dox) with VEGF-targeting siRNAs for an enhanced decrease in VEGF expression. Besides, VEGF-B gene therapy was found to suppress the cardiotoxicity effects of Dox. On the other hand, even though Dox is a commonly used anti-cancer agent, its mechanism of actions isn't completely mapped out. Herein, the interactions between a G4 structure formed by the VEGF promoter region Pu-22 and Dox were investigated.